We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pathogen Reduction Evaluated in Treated Whole Blood

By LabMedica International staff writers
Posted on 21 Feb 2012
The survival of a parasite that can be transmitted by blood transfusion has been ascertained in whole blood treated with a commercial system. More...


The system which uses riboflavin (RB) and ultraviolet (UV) light to inactivate pathogens was used to reduce the levels of infectious Trypanosoma cruzi, the causative agent of Chagas disease in whole blood.

At the American Red Cross (Rockville, MD, USA), scientists inoculated with 4, 40, 400, and 4,000 trypomastigotes/mL into units of whole blood. The blood was transferred to Mirasol illumination bags, with the addition of 35 mL of 500 µmol/L RB solution, and the bag illumination of with UV light. The units were illuminated with 60, 80, and 110 joules/mL of red blood cells, with sample removal after delivery of each dose. Samples were collected pre- and post-illumination and cultured for the hemoflagellates

All preillumination samples exhibited T. cruzi growth in hemoculture, while postillumination samples from units containing 4 and 40 trypomastigotes/mL showed no signs of viable parasites after 16 weeks of culture. In contrast, at both 400 and 4,000 parasites/mL, two of the three units were positive for viable parasites. The total log reduction observed for T. cruzi was 3.5 log or greater, but less than 4.5 log. This level of reduction is likely to be orders of magnitude higher than what would be expected in a tainted blood donation.

The data from the study suggests that the Mirasol System (CaridianBCT; Lakewood, CO, USA) is able to inactivate clinically relevant amounts of T. cruzi in whole blood and it could be a viable alternative to a serologic screening assay. Additionally, this approach would avoid the need for multiple individual screening tests for other agents in a wide spectrum of marginal risks. Considering the challenges associated with T. cruzi testing, the Mirasol System could represent a useful tool in the quest for blood safety, indicating that the system could be effective at preventing transfusion of the causative agent of Chagas disease.

It has been shown that two decades after immigration, 33/52 (63%) of selected blood donors had polymerase chain reaction evidence of parasitemia and three also had culture-confirmed infection. This affirmation that bloodstream parasites are detectable and potentially transmissible, decades after immigration strengthens the rationale for donor screening or whole blood treatment. The study was published in the February 2012 edition of the journal Transfusion.

Related Links:
American Red Cross
CaridianBCT


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.